TCIM
ARRY

TIAA CREF Investment Management’s Array Biopharma Inc ARRY Stock Holding History

TIAA CREF Investment Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$19.8M Buy
811,088
+13,595
+2% +$283K 0.01% 712
2018
Q4 		$11.4M Buy
797,493
+21,298
+3% +$323K 0.01% 893
2018
Q3 		$11.8M Sell
776,195
-247,593
-24% -$3.79M 0.01% 1017
2018
Q2 		$17.2M Sell
1,023,788
-38,367
-4% -$610K 0.01% 822
2018
Q1 		$17.3M Buy
1,062,155
+233,416
+28% +$3.74M 0.01% 823
2017
Q4 		$10.6M Buy
828,739
+70,019
+9% +$796K 0.01% 1104
2017
Q3 		$9.33M Buy
758,720
+188,538
+33% +$1.75M 0.01% 1199
2017
Q2 		$4.77M Sell
570,182
-33,346
-6% -$273K ﹤0.01% 1625
2017
Q1 		$5.4M Sell
603,528
-147,912
-20% -$1.57M ﹤0.01% 1547
2016
Q4 		$6.61M Buy
751,440
+127,196
+20% +$936K ﹤0.01% 1419
2016
Q3 		$4.21M Sell
624,244
-46,913
-7% -$181K ﹤0.01% 1718
2016
Q2 		$2.39M Buy
671,157
+17,866
+3% +$58.2K ﹤0.01% 2006
2016
Q1 		$1.93M Buy
653,291
+203,000
+45% +$608K ﹤0.01% 2097
2015
Q4 		$1.9M Sell
450,291
-14,103
-3% -$64.4K ﹤0.01% 2187
2015
Q3 		$2.12M Sell
464,394
-108,722
-19% -$645K ﹤0.01% 2100
2015
Q2 		$4.13M Buy
573,116
+8,906
+2% +$65.7K ﹤0.01% 1815
2015
Q1 		$4.16M Buy
564,210
+100,294
+22% +$714K ﹤0.01% 1768
2014
Q4 		$2.19M Sell
463,916
-12,909
-3% -$51.1K ﹤0.01% 2170
2014
Q3 		$1.7M Sell
476,825
-20,386
-4% -$80.4K ﹤0.01% 2328
2014
Q2 		$2.27M Buy
497,211
+25,837
+5% +$107K ﹤0.01% 2230
2014
Q1 		$2.21M Sell
471,374
-6,720
-1% -$33.8K ﹤0.01% 2180
2013
Q4 		$2.4M Buy
478,094
+6,841
+1% +$37.2K ﹤0.01% 2142
2013
Q3 		$2.93M Sell
471,253
-16,232
-3% -$96.4K ﹤0.01% 1959
2013
Q2 		$2.21M Buy
+487,485
New +$2.62M ﹤0.01% 2104

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TIAA CREF Investment Management's ARRY Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Array Biopharma Inc (ARRY) stake by 1.7% in Q1 2019, buying an estimated $283K and bringing the position to 811,088 shares worth $19.8M. The position accounts for 0.01% of the portfolio, ranked #712.

TIAA CREF Investment Management first reported a position in ARRY in Q2 2013 and has held it in 24 quarters since. 268 funds tracked by Wall St. Rank hold ARRY as of Q1 2019.

  • TIAA CREF Investment Management held 811,088 shares of Array Biopharma Inc worth $19.8M as of Q1 2019.
  • TIAA CREF Investment Management bought 13,595 Array Biopharma Inc shares in Q1 2019, an estimated $283K.
  • Array Biopharma Inc made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #712 holding.
  • TIAA CREF Investment Management first reported a position in Array Biopharma Inc in Q2 2013 and has held it in 24 quarters since.
  • 268 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.